Drug Linked to Increased Cases of Brain Hemorrhage
The increase in hemorrhage, says UC assistant professor and study author Matthew Flaherty, MD, is due to greater use of the drug warfarin, which is commonly prescribed to prevent blood clotting but carries the side-effect of bleeding.
The use of warfarin increased in the 1990s after studies showed it reduced the risk of stroke caused by blood clots for people with atrial fibrillation, a condition that causes irregular heart rhythm and becomes more common as people age. Blood clots can lead to ischemic stroke, the most common type of stroke. An intracerebral hemorrhage is a stroke caused by bleeding in the brain.
For the study, researchers identified all patients in the greater
Because warfarin is currently the best way to prevent blood clots in patients with atrial fibrillation, Flaherty cautions that its use should not necessarily be discontinued.
Warfarin is highly effective in preventing ischemic stroke among people with atrial fibrillation, said Flaherty. For many people, the benefits of preventing ischemic stroke continue to outweigh the risk of a hemorrhagic stroke.
Our findings should not discourage the use of warfarin when its appropriate. Doctors can use these findings to make sure they are weighing the risks and benefits of warfarin use for their patients. For researchers, these results may stimulate efforts to develop safer alternatives to warfarin and better treatments for people with brain hemorrhages.
Stroke is the third leading cause of death in the
The study was supported in part by the National Institute of Neurological Disorders and Stroke.
Coauthors include Kathleen Alwell, Joseph Broderick, MD,
Matthew Flaherty, MD, is studying the effects of the blood-thinning drug warfarin on stroke patients.
Stroke researcher Dawn Kleindorfer, MD
Joseph Broderick, MD
Tags
Related Stories
UC radiation oncologist speaks with Local 12 news about clinical trial for head and neck cancer treatment
August 10, 2026
Dr. Sara Medek, a UC radiation oncology professor, speaks with Local 12 news about a new clinical trial aimed at reducing radiation in certain areas while still treating cancer effectively but with fewer painful side effects.
Cancer Center director charts future based on collaboration, AI
August 10, 2026
David Gius, MD, PhD, was featured in a Cincinnati Business Courier article and The Cancer Letter’s “The Directors" podcast discussing his priorities and goals as he recently took the helm as director of the University of Cincinnati Cancer Center.
Bidirectional link between oral, kidney health calls for patient education, access
August 4, 2026
Despite growing awareness of the connection between oral health and chronic health conditions, patient awareness and access to dental care remain limited, according to University of Cincinnati experts who recently spoke with Healio | Nephrology News & Issues.